Clinical trial
A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer.
NCT05753657 is registered in ClinicalTrials.gov with Rambam Health Care Campus as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer.
- Lead sponsor
- Rambam Health Care Campus
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- December 25, 2022
- Completion date
- December 31, 2027
- Enrollment
- 30 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
hyperglycemia drug induced, hyperinsulinism, metastatic breast cancer